A Review: Traditional Herbs and Remedies Impacting Pathogenesis of Parkinson's Disease

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2022 Mar 8

PMID 35258640

Authors

Vishavdeep Sharma

Onkar Bedi

Manisha Gupta

Rahul Deshmukh

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons, leading to misbalance and loss of coordination. Current therapies are claimed only for symptomatic relief, on long-term use, which causes alteration in basal ganglia, and give rise to various adverse effects like dyskinesia and extra pyramidal side effects, which is reversed and proved to be attenuated with the help of various herbal approaches. Therefore, in order to attenuate the dopaminergic complications, focus of current research has been shifted from dopaminergic to non-dopaminergic strategies. Herbs and herbal remedies seems to be a better option to overcome the complications associated with current dopaminergic therapies. In recent years, various herbs and herbal remedies based on Ayurveda, traditional Chinese and Korean remedies, have become the target of various researches. These herbs and their bioactive compound are being extensively used to treat PD in India, China, Japan, and Korea. The major focus of this current review is to analyze preclinical studies with reference to various herbs, bioactive compounds, and traditional remedies for the management of Parkinson disorder, which will give an insight towards clinical trials.

Citing Articles

Molecular targets and mechanisms of Sijunzi decoction in the treatment of Parkinson's disease: evidence from network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation.

Jiang Y, Wu W, Xie L, Zhou Y, Yang K, Wu D Front Pharmacol. 2024; 15:1487474.

PMID: 39660000 PMC: 11629541. DOI: 10.3389/fphar.2024.1487474.

Nrf2 and Ferroptosis: Exploring Translational Avenues for Therapeutic Approaches to Neurological Diseases.

Mohan M, Mannan A, Kakkar C, Singh T Curr Drug Targets. 2024; 26(1):33-58.

PMID: 39350404 DOI: 10.2174/0113894501320839240918110656.

Neuroprotective properties of the Lilium brownii extracts in the experimental model of Parkinson's disease.

Hui C, Jin J, Ji M, Wang H, Wang X, Ma J Metab Brain Dis. 2024; 39(6):1085-1097.

PMID: 39060803 DOI: 10.1007/s11011-024-01397-6.

Nutritional and pharmacological potentials of orphan legumes: Subfamily faboideae.

Ogbole O, Akin-Ajani O, Ajala T, Ogunniyi Q, Fettke J, Odeku O Heliyon. 2023; 9(4):e15493.

PMID: 37151618 PMC: 10161725. DOI: 10.1016/j.heliyon.2023.e15493.

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease.

Yan Y, Xu Z, Wang J, Yu W Front Pharmacol. 2022; 13:1007556.

PMID: 36249800 PMC: 9556873. DOI: 10.3389/fphar.2022.1007556.

References

Ahmad M, Saleem S, Ahmad A, Ansari M, Yousuf S, Hoda M . Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol. 2005; 24(3):137-47. DOI: 10.1191/0960327105ht509oa. View

Ahmed I, Bose S, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G . Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain. 2011; 134(Pt 4):979-86. DOI: 10.1093/brain/awr028. View

Alberio T, Lopiano L, Fasano M . Cellular models to investigate biochemical pathways in Parkinson's disease. FEBS J. 2012; 279(7):1146-55. DOI: 10.1111/j.1742-4658.2012.08516.x. View

Alfinito P, Wang S, Manzino L, Rijhsinghani S, Zeevalk G, Sonsalla P . Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci. 2003; 23(34):10982-7. PMC: 6740986. View

Amro M, Teoh S, Norzana A, Srijit D . The potential role of herbal products in the treatment of Parkinson's disease. Clin Ter. 2018; 169(1):e23-e33. DOI: 10.7417/T.2018.2050. View

An H, Kim I, Koppula S, Kim B, Park P, Lim B . Protective effects of Gastrodia elata Blume on MPP+-induced cytotoxicity in human dopaminergic SH-SY5Y cells. J Ethnopharmacol. 2010; 130(2):290-8. DOI: 10.1016/j.jep.2010.05.006. View

Bae N, Ahn T, Chung S, Oh M, Ko H, Oh H . The neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement in models of Parkinson's disease. J Ethnopharmacol. 2010; 134(2):313-22. DOI: 10.1016/j.jep.2010.12.016. View

Binde C, Tvete I, Gasemyr J, Natvig B, Klemp M . A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. Br J Clin Pharmacol. 2018; 84(9):1917-1927. PMC: 6089809. DOI: 10.1111/bcp.13651. View

Braak H, Del Tredici K . Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered. Exp Neurol. 2008; 212(1):226-9. DOI: 10.1016/j.expneurol.2008.04.001. View

10.

Bridi R, Crossetti F, Steffen V, Henriques A . The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res. 2001; 15(5):449-51. DOI: 10.1002/ptr.814. View

11.

Bureau G, Longpre F, Martinoli M . Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res. 2007; 86(2):403-10. DOI: 10.1002/jnr.21503. View

12.

Chao J, Yu M, Ho Y, Wang M, Chang R . Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med. 2008; 45(7):1019-26. DOI: 10.1016/j.freeradbiomed.2008.07.002. View

13.

Chen X, Zhu Y, Zhu L, Huang C, Chen Y, Chen L . Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur J Pharmacol. 2003; 473(1):1-7. DOI: 10.1016/s0014-2999(03)01945-9. View

14.

Cheng Y, He G, Mu X, Zhang T, Li X, Hu J . Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile. Neurosci Lett. 2008; 441(1):16-20. DOI: 10.1016/j.neulet.2008.05.116. View

15.

Choi J, Kim H, Kim M, Yang W, Huh Y, Kim S . Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models. J Ethnopharmacol. 2011; 134(2):414-21. DOI: 10.1016/j.jep.2010.12.030. View

16.

Dawson T, Dawson V . Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest. 2003; 111(2):145-51. PMC: 151882. DOI: 10.1172/JCI17575. View

17.

Drechsel D, Patel M . Differential contribution of the mitochondrial respiratory chain complexes to reactive oxygen species production by redox cycling agents implicated in parkinsonism. Toxicol Sci. 2009; 112(2):427-34. PMC: 2777080. DOI: 10.1093/toxsci/kfp223. View

18.

Fabbrini G, Brotchie J, Grandas F, Nomoto M, Goetz C . Levodopa-induced dyskinesias. Mov Disord. 2007; 22(10):1379-1389. DOI: 10.1002/mds.21475. View

19.

Filomeni G, Graziani I, De Zio D, Dini L, Centonze D, Rotilio G . Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson's disease. Neurobiol Aging. 2010; 33(4):767-85. DOI: 10.1016/j.neurobiolaging.2010.05.021. View

20.

Forloni G, Bertani I, Calella A, Thaler F, Invernizzi R . Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol. 2000; 47(5):632-40. View